Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

NCT06634589 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT06634589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06634589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
Lead sponsor
BeOne Medicines
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 27, 2024
Completion date
December 2, 2029
Enrollment
80 (estimated)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, b-cell malignancy, refractory cancer, relapsed cancer